KDR and hepatocellular carcinoma: Having observed that MET and VEGFR2 inhibitors inhibited proliferation of MET-amplified and MET/P-MET-high–expressing HCC cells in vitro, we next evaluated the potential action of NZ001 to MHCC97H (MET amplification and high MET protein expression) and Huh7 (non-MET amplification and low MET protein expression) xenograft models in vivo.